Lexaria Bioscience Corp (LEXXW)

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing ...

KELOWNA, BC / ACCESSWIRE / April 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the Company is receiving its first-ever patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs.

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing ...

KELOWNA, BC / ACCESSWIRE / April 19, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that it has begun its multi-week human clinical hypertension study.

Data From This Human Study, Together With the Findings From Lexaria's Other Previously Announced Successful Studies, Intended To Support the Company's Plans To Seek Approvals by the U.S. Food and Drug Administration

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing ...

KELOWNA, BC / ACCESSWIRE / April 12, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces details of human nicotine study NIC-H22-1, which is expected to begin dosing this summer.

KELOWNA, BC / ACCESSWIRE / April 11, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has entered new agreements with Altria Client Services, LLC ("Altria").

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing ...

KELOWNA, BC / ACCESSWIRE / March 15, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that the first phase of its epilepsy research program EPIL-A21-1 is beginning this week, and the DehydraTECHTM-CBD test articles needed to commence dosing have already been manufactured and delivered to the third-party laboratory engaged to complete this research program.

Newest granted patent expands worldwide patent portfolio to 24

DehydraTECHTM sildenafil delivered 74% more drug at 4 minutes, than the control

NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN (InvestorBrandNetwork), a multifaceted financial news and publishing company for private and public entities, today announces that Chris Bunka, Chairman and CEO of Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently appeared on the EDGE Podcast, a series focused on providing the business owner's playbook about the inner game of building a successful business and giving listeners the e

Detroit, Michigan--(Newsfile Corp. - December 6, 2021) - Lexaria Bioscience Corp. (NASDAQ: LEXX) will be presenting at the Benzinga Global Small Cap Conference taking place on December 8-9, 2021. We invite our shareholders and all interested parties to explore investment opportunities within the global small cap space. Sign up to get a free spectator pass for the event: https://www.benzinga.com/events/small-cap/december-2021-global/. About the Benzinga Global Small Cap Conference ...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...